BIOS — Biosenic SA Share News
0.000.00%
Last trade - 00:00Brief: Biosenic Anticipates Having Sufficient Cash To Carry Out Its Business Objectives Until Q3 2024
Brief: BioSenic Patent Granted In Canada For Broader Protection Of ATO Therapeutic Platform
Brief: Biosenic Files For Additional Patent Protection For Osteoarthritis Drug
Brief: BioSenic Signs New Binding Term Sheet With Phebra PTY Ltd
Brief: Biosenic On Its Way To Find Funds For Clinical Trial On Chronic Graft-Versus-Host Disease
Brief: BioSenic Net Cash At End-Sept At EUR 0.39 Million
Brief: BioSenic Start Of SLE, SSC Phase 2 Clinical Trials Not Envisioned Before 2025
Brief: Biosenic Reaches Agreement With Global Tech Opportunities 15 To Finalise Bonds Programme
Brief: Biosenic Announces New Developments In Phase 2 Clinical Trial For Arsenic Trioxide In cGvHD
Brief: Biosenic Publishes New Evidence Of Beneficial Effects Of Arsenic Trioxide Treatment Supporting Clinical Trial For Systemic Sclerosis
Brief: Biosenic Puts Phase IIb ALLOB Trial On Hold
Brief: Biosenic Updates On Current License Agreement With Phebra
Brief: Biosenic To Potentially Receive Royalty Rates On Net Sales Up To 25%
Brief: Biosenic ALLOB PHASE IIB Topline Results Foreseen In Q2 2023
Brief: Biosenic Receives Key European Patent From EPO For Further Therapeutic Development
Brief: Biosenic Expects Having Sufficient Cash To Carry Out Its Business Objectives Until May 2023
Brief: Biosenic Publishes New Data On Mechanism Of Action Of Arsenic Trioxide
Brief: BioSenic Announces Publication OF Listing Prospectus, Admission To Trading Of Shares and Subscription Rights
Brief: Biosenic Appoints Dr Carole Nicco As Chief Scientific Officer